WO2019202521A1 - Oral disintegrating film compositions of paracetamol - Google Patents
Oral disintegrating film compositions of paracetamol Download PDFInfo
- Publication number
- WO2019202521A1 WO2019202521A1 PCT/IB2019/053158 IB2019053158W WO2019202521A1 WO 2019202521 A1 WO2019202521 A1 WO 2019202521A1 IB 2019053158 W IB2019053158 W IB 2019053158W WO 2019202521 A1 WO2019202521 A1 WO 2019202521A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- total weight
- film composition
- paracetamol
- fast dissolving
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Definitions
- the present invention relates to fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is to be masked. More specifically, the present invention relates to a fast dissolving film composition containing paracetamol and taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- the present invention relates to an orally fast dissolving film composition containing of at least 40% w/w paracetamol based on the total weight of film composition and taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- Paracetamol or Acetaminophen or 4'-hydroxyacetanilide is the most commonly used non-steroidal anti-inflammatory antipyretic analgesics for fever common cold or influenza bowl also used to relieve mild to moderate pain such as headaches, joint pain, migraine, toothache, muscle pain, neuralgia, dysmenorrhea. Moreover, paracetamol is the World Health Organization recommended the most effective and safe for children antipyretics for children with fever caused by the common cold or influenza have a good effect.
- Acetaminophen is chemically N-(4-Hydroxyphenyl) acetamide represented below.
- Products containing paracetamol are marketed in the form of tablet, capsule, suspension, effervescent, intravenous and intramuscular form.
- Paracetamol can be used in adults in the dose range of 500 mg to 1000 mg. The maximum daily dose for adults is 4000 mg.
- Paracetamol is recommended as the first-line drug for geriatric patients over 50 years old and for the pain and aches seen in influenza.
- paracetamol As well as the preferred route of paracetamol administration is oral, paracetamol is also well-known with its bitter taste.
- Paracetamol characteristic feature is its searing taste and leaving an unpleasant taste in the throat after swallowing. In the case of contact with mouth or throat mucosa, an unpleasant taste is felt.
- Oral dissolving films are gaining interest as an alternative of fast dissolving tablets.
- the films are designed to dissolve upon contact with a wet surface, such as the tongue, within a few seconds, meaning the consumer can take the product without need for additional liquid.
- This convenience provides both a marketing advantage and increased patient compliance.
- Over-the-counter films for pain management and motion sickness are commercialized in the US markets.
- the oral route is one of the most preferred routes of drug administration as it is more convenient, cost effective, and ease of administration lead to high level of patient compliance.
- the oral route is problematic because of the swallowing difficulty for pediatric and geriatric patients who have fear of choking.
- Patient convenience and compliance oriented research has resulted in bringing out safer and newer drug delivery systems.
- fast dissolving drug delivery systems have started gaining popularity and acceptance as one such example with increased consumer choice, for the reason of rapid disintegration or dissolution, self-administration even without water or chewing as to overcome swallowing difficulties associated with tablets and capsules for pediatric and geriatric patients.
- the surface of buccal cavity comprises of stratified squamous epithelium which is essentially separated from the underlying tissue of lamina limba and submucosa by an undulating basement membrane. It is interesting to note that the permeability of buccal mucosa is approximately 4-4,000 times greater than that of the skin, but less than that of the intestine.
- An ideal fast dissolving delivery system should have the following properties: High stability, transportability, ease of handling and administration, no special packaging material or processing requirements, no water necessary for application, and a pleasant taste. Therefore, they are very suitable for pediatric and geriatric patients; bedridden patients; or patients suffering from dysphagia, parkinson's disease, Mucositis, or vomiting.
- Formulation of fast dissolving buccal film involves material such as strip-forming polymers, plasticizers, active pharmaceutical ingredient, sweetening agents, saliva stimulating agent, flavoring agents, coloring agents, stabilizing and thickening agents, permeation enhancers, and superdisintegrants.
- Patent No. US 8,216,610 discloses the swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration.
- Patent NO. EP0421825 discloses the rally administrable solution comprising an analgesic as active ingredient and a solvent therefor which solvent contains polyethylene glycol.
- PCT application NO. WO2016024928 discloses the taste masked oral pharmaceutical formulations where active ingredient is paracetamol and metallic salts are used.
- Patent application CN1679525 discloses the acetaminophen orally disintegrating tablet.
- Rutesh H. Dave et al discloses the develop and evaluate physicochemical properties of acetaminophen and aspirin orally disintegrating strips with high loading dose.
- Oral disintegrating film as disclosed in above prior art does not provide the desirable film properties with paracetamol that have high drug loading and further whose bitter taste is masked. Bitter taste masking of an active ingredient inevitably leads to poor physical properties and brittleness.
- present invention aims to provide oral disintegrating film and process for manufacturing the same to mask the bitterness of paracetamol with high drug loading. It relates more specifically oral disintegrating film containing paracetamol and taste masking agent.
- the present invention provides herein, oral disintegrating film composition consisting essentially of a therapeutically effective amount of paracetamol or pharmaceutically acceptable salts thereof and an excipient that facilitates oral administration, and methods of use thereof for antipyretic for children.
- the high dose of paracetamol is not loaded in film formulations of the prior art with the total weight of film composition as it causes a serious problem in the brittleness of the film. Based on this reason, it is an object of the present invention to provide fast dissolving film composition that is free from the problem of brittleness even when a high dose of paracetamol of more than lOOmg is loaded.
- the present inventors have founded that even when at least 40.0% w/w of paracetamol is loaded and the problem of brittleness is solved, the medication compliance of patient upon administration is greatly deteriorated by ineffective masking of the bitter taste of the paracetamol.
- a taste masking agent specifically designed to produce to desired formulation.
- It is a final object of the present invention to provide a fast dissolving film composition comprising of at least 40.0% w/w of paracetamol or a pharmaceutically acceptable salt thereof whose bitter taste is masked by a taste masking agent, wherein taste masking agent is mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- taste masking agent is mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- the present invention is of technical significance in providing a fast dissolving film composition in which at least 40.0% w/w of paracetamol is loaded and the bitter taste of paracetamol is masked without causing any problem in film-forming ability.
- compositions consisting essentially of a therapeutically effective amount of paracetamol and pharmaceutically acceptable excipients that facilitates oral administration and process for manufacturing the same.
- the pharmaceutical composition of the invention is oral disintegrating film or a fast dissolving film composition.
- the pharmaceutical oral disintegrating film composition comprising paracetamol and pharmaceutically acceptable excipients.
- the present invention discloses a fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof and a taste masking agent wherein paracetamol or a pharmaceutically acceptable salt thereof is at least 1 OOmg or at least 40.0% w/w by weight with respect to the total weight of the film.
- Paracetamol is preferably used in a pharmaceutical oral disintegrating film/fast dissolving film composition of about 40.0% w/w to about 60.0% w/w based on the total weight of the composition. More preferable concentration of paracetamol in the composition is about 45.0% w/w to about 55.0% w/w by total weight of the composition and most preferable is of about 45.0% w/w to about 50.0% w/w based on the total weight of film composition.
- the present invention relates to a fast dissolving film composition
- a fast dissolving film composition comprising paracetamol, solubilizer, disintegrant and a taste masking agent.
- the present invention relates to a fast dissolving film composition
- a fast dissolving film composition comprising paracetamol, solubilizer, disintegrant and a taste masking agent, when the ratio of solubilizer and disintegrant is of about 1 : 3 to about 3: 1.
- the solubilizer is selected from the group consisting of benzyl alcohol, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-b- cyclodextrin.
- the solubilizer selected is hydroxypropyl-P-cyclodextrin.
- Hydroxypropyl-P-cyclodextrin preferably used in the pharmaceutical oral disintegrating film/fast dissolving film composition is of about 0.1% w/w to about 10.0% w/w based on the total weight of the composition.
- hydroxypropyl-P-cyclodextrin used in the composition of about 1.0% w/w to about 5.0% w/w based on total weight of the composition.
- the disintegrant is selected from the group consisting of sodium starch glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose and combinations thereof.
- disintegrant used in the composition is silicified microcrystalline cellulose.
- Silicified microcrystalline preferably used in the pharmaceutical oral disintegrating film/fast dissolving film composition is of about 1.0% w/w to about 20.0% w/w based on the total weight of the composition. More preferably, silicified microcrystalline cellulose used in the composition of about 5.0% w/w to about 15.0% w/w based on total weight of the composition and most preferably of about 5.0% w/w to about 10.0% w/w based on total weight of the composition.
- the taste masking agent is selected from the group consisting of sodium carbonate, citric acid and magnesium aluminometasilicate.
- the taste masking agent is mixture of sodium carbonate, citric acid and magnesium aluminometasilicate in the ratio of 1 : 4.5: 7.5.
- the taste masking agent mixture consists of about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition.
- the present invention relates to a fast dissolving film composition
- a fast dissolving film composition comprising
- solubilizer selected from the group consisting of benzyl alcohol, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-b- cyclodextrin;
- disintegrant selected from the group consisting of sodium starch glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose;
- taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- the present invention relates to a fast dissolving film composition consisting essentially of
- solubilizer selected from the group consisting of benzyl alcohol, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-b- cyclodextrin;
- disintegrant selected from the group consisting of sodium starch glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose;
- taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- the present invention relates to a fast dissolving film composition
- a fast dissolving film composition comprising of
- the present invention relates to a fast dissolving film composition consisting essentially of
- taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
- the present invention relates to the fast dissolving oral film composition further comprising, polymer, plasticizer, sweetening agents, and at least one excipient selected from colouring agents and flavoring agents.
- polymers used in the invention are selected from the group consisting of hydroxypropyl methylcellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol and cellulose acetate phthalate and combinations thereof.
- the polymer used in the present invention is hydroxylpropyl methyl cellulose (HPMC El 5).
- Hydroxylpropyl methyl cellulose preferably used in the pharmaceutical oral disintegrating film composition is of about 10.0% w/w to about 25.0% w/w based on the total weight of the composition.
- hydroxypropyl methylcellulose used in the present invention is about 15.0% w/w to about 25.0% w/w hydroxypropyl methylcellulose and most preferably about 12.0% w/w to about 20.0% w/w based on total weight of the composition.
- plasticizers used in the present invention are selected from the group consisting of polyethylene glycol, diethyl phthalate, propylene glycol and glycerol and combinations thereof.
- the plasticizer used in the present invention is glycerol.
- Glycerol preferably used in the pharmaceutical oral disintegrating film composition is of about 0.1% w/w to about 10.0% based on the total weight of the composition. Most preferably, glycerol is used in the composition of about 1.0% w/w to about 5.0% w/w based on total weight of the composition.
- sweetening agents are selected from the group consisting of aspartame, sucralose, dextrose, fructose, ammonium glycyrrhizinate, maltose, mannitol, sorbitol and xylitol and/or combinations thereof.
- the sweetening agent used in the present invention is a mixture of sucralose and xylitol.
- the pharmaceutical composition comprises a mixture of xylitol and sucralose in a ratio of about 3: 1 to about 1 :3 as the sweetening agent. More preferably sweetening agent mixture consists of about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition.
- flavour agents are selected from the group consisting of peppermint flavour, cooling flavour (menthol), flavour oils, flavouring aromatic oil, peppermint oil, clove oil, bay oil, anise oil, eucalyptus oil thyme oil, oil of bitter almonds.
- Flavouring agents include, vanilla, chocolate flavour, citrus oils, fruit essences, and any combinations thereof.
- the flavour agents are selected from menthol (polo mint) and chocolate flavour.
- Flavour agents preferably used in the pharmaceutical oral disintegrating film composition of about 5% to about 20% based on the total weight of the composition.
- the colouring agent are selected from the group consisting of sunset yellow, amaranth, red iron oxide, natural juice concentrates, pigments and opacifying agents such as titanium oxide, silicon dioxide and zinc oxide, solid choco color and any combinations thereof.
- the coloring agent is selected from solid choco color.
- Colouring agent preferably used in the pharmaceutical oral disintegrating film composition of about 0.001% to about 0.1% based on the total weight of the composition. Most preferably, colouring agent is used in the composition of about 0.01% to about 0.08% based on total weight of the composition.
- the present invention relates to a fast dissolving film composition
- a fast dissolving film composition comprising of
- e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
- sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
- the present invention relates to a fast dissolving film composition consisting essentially of a) about 45.0% w/w to about 50.0% w/w paracetamol based on total weight of film composition;
- e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
- sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
- the present invention relates to a fast dissolving film composition consisting of
- e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
- sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
- the oral film formulation of the present invention is formed into a thin film while maintaining tensile strength and toughness at desired levels.
- the oral film formulation of the present invention has a thickness of about 50 pm to about 1500 pm.
- the oral film formulation of the present invention has a size of about 1 cm 2 to about 12 cm 2 , preferably 2 cm 2 to about 10 cm 2 .
- compositions for oral film preparations were shown in Table- 1.
- the pH values, bitter taste scores, were evaluated based on the following criteria. •
- compositions of Table 1 are not in scope of the claims.
- Example-5 when the mixture of sodium carbonate, citric acid and Magnesium aluminometasilicate are used in ratio of 1 : 4.5: 7.5 (Example-5), the bitter taste of paracetamol was effectively masked.
- the composition of Example-5 comprises of 0.15% w/w of sodium carbonate, 0.7% w/w of citric acid and 1.2% of magnesium aluminometasilicate for which the taste of paracetamol was masked.
- Example - 5 Dissolution profile of Example - 5 was done in pH 1.2 Media (HC1 Buffer), pH 4.5 Media (acetate buffer) and pH 6.8 Media (Phosphate buffer) in paddle apparatus at 50 RPM with volume of 900 mL and release profile is as depicted in Table -3.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is to be masked. More specifically, the present invention relates to a fast dissolving film composition containing paracetamol and taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
Description
ORAL DISINTEGRATING FILM COMPOSITIONS OF
PARACETAMOL
FIELD OF THE INVENTION
The present invention relates to fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is to be masked. More specifically, the present invention relates to a fast dissolving film composition containing paracetamol and taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
Further, the present invention relates to an orally fast dissolving film composition containing of at least 40% w/w paracetamol based on the total weight of film composition and taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
BACKGROUND OF THE INVENTION
Paracetamol or Acetaminophen or 4'-hydroxyacetanilide is the most commonly used non-steroidal anti-inflammatory antipyretic analgesics for fever common cold or influenza bowl also used to relieve mild to moderate pain such as headaches, joint pain, migraine, toothache, muscle pain, neuralgia, dysmenorrhea. Moreover, paracetamol is the World Health Organization recommended the most effective and safe for children antipyretics for children with fever caused by the common cold or influenza have a good effect. Acetaminophen is chemically N-(4-Hydroxyphenyl) acetamide represented below.
Products containing paracetamol are marketed in the form of tablet, capsule, suspension, effervescent, intravenous and intramuscular form. Paracetamol can be used in adults in the dose range of 500 mg to 1000 mg. The maximum daily dose for adults is 4000 mg. Paracetamol is recommended as the first-line drug for geriatric patients over 50 years old and for the pain and aches seen in influenza.
As well as the preferred route of paracetamol administration is oral, paracetamol is also well-known with its bitter taste. Paracetamol characteristic feature is its searing taste and leaving an unpleasant taste in the throat after swallowing. In the case of contact with mouth or throat mucosa, an unpleasant taste is felt. There is a need to mask/, inhibit the bitter taste of paracetamol given in disintegrated form during oral use such as syrup, effervescent tablet, oral disintegrating tablet. Even today, there is patient’s complication about bitter taste left in mouth or throat after administrating paracetamol effervescent tablet. It is mentioned that even paracetamol syrups are having strong bitter taste couldn't mask by sweetening agents.
Oral dissolving films are gaining interest as an alternative of fast dissolving tablets. The films are designed to dissolve upon contact with a wet surface, such as the tongue, within a few seconds, meaning the consumer can take the product without need for additional liquid. This convenience provides both a marketing advantage and increased patient compliance. As the drug is directly absorbed into systemic circulation, degradation in gastrointestinal tract and first pass effect can be avoided. These points make this formulation most popular and acceptable among pediatric and geriatric patients and patients with fear of choking. Over-the-counter films for pain management and motion sickness are commercialized in the US markets.
The oral route is one of the most preferred routes of drug administration as it is more convenient, cost effective, and ease of administration lead to high level of patient compliance. The oral route is problematic because of the swallowing difficulty for pediatric and geriatric patients who have fear of choking. Patient convenience and compliance oriented research has resulted in bringing out safer and newer drug delivery systems. Recently, fast dissolving drug delivery systems have started gaining popularity and acceptance as one such example with increased consumer choice, for the reason of rapid disintegration or dissolution, self-administration even without water or chewing as to overcome swallowing difficulties associated with tablets and capsules for pediatric and geriatric patients. The surface of buccal cavity comprises of stratified squamous epithelium which is essentially separated from the underlying tissue of lamina propria and submucosa by an undulating basement membrane. It is interesting to note that the permeability of buccal mucosa is approximately 4-4,000 times greater than that of the skin, but less than that of the intestine.
An ideal fast dissolving delivery system should have the following properties: High stability, transportability, ease of handling and administration, no special packaging material or processing requirements, no water necessary for application, and a pleasant taste. Therefore, they are very suitable for pediatric and geriatric patients; bedridden patients; or patients suffering from dysphagia, parkinson's disease, Mucositis, or vomiting. Formulation of fast dissolving buccal film involves material such as strip-forming polymers, plasticizers, active pharmaceutical ingredient, sweetening agents, saliva stimulating agent, flavoring agents, coloring agents, stabilizing and thickening agents, permeation enhancers, and superdisintegrants.
Patent No. US 8,216,610 discloses the swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration.
Patent NO. EP0421825 discloses the rally administrable solution comprising an analgesic as active ingredient and a solvent therefor which solvent contains polyethylene glycol.
PCT application NO. WO2016024928 discloses the taste masked oral pharmaceutical formulations where active ingredient is paracetamol and metallic salts are used.
Patent application CN1679525 discloses the acetaminophen orally disintegrating tablet.
Rutesh H. Dave et al, (Development and evaluation of high loading oral dissolving film of aspirin and acetaminophen) discloses the develop and evaluate physicochemical properties of acetaminophen and aspirin orally disintegrating strips with high loading dose.
Ikumi Ito et al, (Preparation of an oral acetaminophen film that is expected to improve medication administration: Effect of polyvinylpyrrolidone on physical properties of the film) discloses the effect of polyvinylpyrrolidone (PVP) on a film containing carboxymethyl cellulose sodium (CMC) as a matrix to improve surface roughness caused by drug recrystallization. Acetaminophen (AA) was used as the model drug.
Oral disintegrating film as disclosed in above prior art does not provide the desirable film properties with paracetamol that have high drug loading and further whose bitter
taste is masked. Bitter taste masking of an active ingredient inevitably leads to poor physical properties and brittleness.
Therefore, present invention aims to provide oral disintegrating film and process for manufacturing the same to mask the bitterness of paracetamol with high drug loading. It relates more specifically oral disintegrating film containing paracetamol and taste masking agent.
SUMMARY OF THE INVENTION
In one object, the present invention provides herein, oral disintegrating film composition consisting essentially of a therapeutically effective amount of paracetamol or pharmaceutically acceptable salts thereof and an excipient that facilitates oral administration, and methods of use thereof for antipyretic for children.
It is an object of the present invention to provide fast dissolving film composition including at least of about 40.0% w/w of paracetamol based on the total weight of the film composition. The high dose of paracetamol is not loaded in film formulations of the prior art with the total weight of film composition as it causes a serious problem in the brittleness of the film. Based on this reason, it is an object of the present invention to provide fast dissolving film composition that is free from the problem of brittleness even when a high dose of paracetamol of more than lOOmg is loaded. Further the present inventors have founded that even when at least 40.0% w/w of paracetamol is loaded and the problem of brittleness is solved, the medication compliance of patient upon administration is greatly deteriorated by ineffective masking of the bitter taste of the paracetamol. Considering this finding, it is another object of the present invention to provide a taste masking agent specifically designed to produce to desired formulation.
Particularly, it is an object of the present invention to provide a fast dissolving film composition of paracetamol whose bitter taste is masked by a specific taste masking agent and/or a mixture of specific taste masking agents. Furthermore, it is an object of the present invention to provide a pharmaceutical composition that has good ability to form an orally fast dissolving film composition comprising paracetamol and or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is masked by a mixture of specific taste masking agents.
It is a final object of the present invention to provide a fast dissolving film composition comprising of at least 40.0% w/w of paracetamol or a pharmaceutically acceptable salt thereof whose bitter taste is masked by a taste masking agent, wherein taste masking agent is mixture of sodium carbonate, citric acid and magnesium aluminometasilicate. Further the present invention is of technical significance in providing a fast dissolving film composition in which at least 40.0% w/w of paracetamol is loaded and the bitter taste of paracetamol is masked without causing any problem in film-forming ability.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides herein, compositions consisting essentially of a therapeutically effective amount of paracetamol and pharmaceutically acceptable excipients that facilitates oral administration and process for manufacturing the same.
In a preferred embodiment, the pharmaceutical composition of the invention is oral disintegrating film or a fast dissolving film composition.
In the most preferred embodiment, the pharmaceutical oral disintegrating film composition comprising paracetamol and pharmaceutically acceptable excipients.
The present invention discloses a fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof and a taste masking agent wherein paracetamol or a pharmaceutically acceptable salt thereof is at least 1 OOmg or at least 40.0% w/w by weight with respect to the total weight of the film.
Paracetamol is preferably used in a pharmaceutical oral disintegrating film/fast dissolving film composition of about 40.0% w/w to about 60.0% w/w based on the total weight of the composition. More preferable concentration of paracetamol in the composition is about 45.0% w/w to about 55.0% w/w by total weight of the composition and most preferable is of about 45.0% w/w to about 50.0% w/w based on the total weight of film composition.
In embodiments of the invention, the present invention relates to a fast dissolving film composition comprising paracetamol, solubilizer, disintegrant and a taste masking agent.
In embodiments of the invention, the present invention relates to a fast dissolving film composition comprising paracetamol, solubilizer, disintegrant and a taste masking agent, when the ratio of solubilizer and disintegrant is of about 1 : 3 to about 3: 1.
The solubilizer is selected from the group consisting of benzyl alcohol, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-b- cyclodextrin. Preferably, the solubilizer selected is hydroxypropyl-P-cyclodextrin. Hydroxypropyl-P-cyclodextrin preferably used in the pharmaceutical oral disintegrating film/fast dissolving film composition is of about 0.1% w/w to about 10.0% w/w based on the total weight of the composition. Most preferably,
hydroxypropyl-P-cyclodextrin used in the composition of about 1.0% w/w to about 5.0% w/w based on total weight of the composition.
The disintegrant is selected from the group consisting of sodium starch glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose and combinations thereof. Preferably disintegrant used in the composition is silicified microcrystalline cellulose. Silicified microcrystalline preferably used in the pharmaceutical oral disintegrating film/fast dissolving film composition is of about 1.0% w/w to about 20.0% w/w based on the total weight of the composition. More preferably, silicified microcrystalline cellulose used in the composition of about 5.0% w/w to about 15.0% w/w based on total weight of the composition and most preferably of about 5.0% w/w to about 10.0% w/w based on total weight of the composition.
The taste masking agent is selected from the group consisting of sodium carbonate, citric acid and magnesium aluminometasilicate. The taste masking agent is mixture of sodium carbonate, citric acid and magnesium aluminometasilicate in the ratio of 1 : 4.5: 7.5.
The taste masking agent mixture consists of about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition.
In embodiments of the invention, the present invention relates to a fast dissolving film composition comprising
a) paracetamol or pharmaceutically acceptable salt thereof;
b) solubilizer selected from the group consisting of benzyl alcohol, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-b- cyclodextrin;
c) disintegrant selected from the group consisting of sodium starch glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose; and
d) taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
In another embodiment of the invention, the present invention relates to a fast dissolving film composition consisting essentially of
a) paracetamol or pharmaceutically acceptable salt thereof;
b) solubilizer selected from the group consisting of benzyl alcohol, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-b- cyclodextrin;
c) disintegrant selected from the group consisting of sodium starch glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose; and
d) taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
In further embodiments of the invention, the present invention relates to a fast dissolving film composition comprising of
a) at least 40% w/w of paracetamol; and
b) taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
In another embodiment of the invention, the present invention relates to a fast dissolving film composition consisting essentially of
a) at least 40% w/w of paracetamol; and
b) taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
In embodiments of the invention, the present invention relates to the fast dissolving oral film composition further comprising, polymer, plasticizer, sweetening agents, and at least one excipient selected from colouring agents and flavoring agents.
In embodiments of the invention, polymers used in the invention are selected from the group consisting of hydroxypropyl methylcellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol and cellulose acetate phthalate and combinations thereof. Preferably, the polymer used in the present invention is hydroxylpropyl methyl cellulose (HPMC El 5). Hydroxylpropyl methyl cellulose preferably used in the pharmaceutical oral disintegrating film composition is of about 10.0% w/w to about 25.0% w/w based on the total weight of the composition. More preferably hydroxypropyl methylcellulose used in the present invention is about 15.0% w/w to about 25.0% w/w hydroxypropyl methylcellulose and most preferably about 12.0% w/w to about 20.0% w/w based on total weight of the composition.
In embodiments of the invention, plasticizers used in the present invention are selected from the group consisting of polyethylene glycol, diethyl phthalate, propylene glycol and glycerol and combinations thereof. Preferably, the plasticizer used in the present invention is glycerol. Glycerol preferably used in the pharmaceutical oral disintegrating film composition is of about 0.1% w/w to about 10.0% based on the total weight of the composition. Most preferably, glycerol is used
in the composition of about 1.0% w/w to about 5.0% w/w based on total weight of the composition.
In embodiments of the invention, sweetening agents are selected from the group consisting of aspartame, sucralose, dextrose, fructose, ammonium glycyrrhizinate, maltose, mannitol, sorbitol and xylitol and/or combinations thereof. Preferably, the sweetening agent used in the present invention is a mixture of sucralose and xylitol. The pharmaceutical composition comprises a mixture of xylitol and sucralose in a ratio of about 3: 1 to about 1 :3 as the sweetening agent. More preferably sweetening agent mixture consists of about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition.
Examples of the flavour agents are selected from the group consisting of peppermint flavour, cooling flavour (menthol), flavour oils, flavouring aromatic oil, peppermint oil, clove oil, bay oil, anise oil, eucalyptus oil thyme oil, oil of bitter almonds. Flavouring agents include, vanilla, chocolate flavour, citrus oils, fruit essences, and any combinations thereof. Preferably, the flavour agents are selected from menthol (polo mint) and chocolate flavour. Flavour agents preferably used in the pharmaceutical oral disintegrating film composition of about 5% to about 20% based on the total weight of the composition.
Examples of the colouring agent are selected from the group consisting of sunset yellow, amaranth, red iron oxide, natural juice concentrates, pigments and opacifying agents such as titanium oxide, silicon dioxide and zinc oxide, solid choco color and any combinations thereof. Preferably, the coloring agent is selected from solid choco color. Colouring agent preferably used in the pharmaceutical oral disintegrating film composition of about 0.001% to about 0.1% based on the total weight of the
composition. Most preferably, colouring agent is used in the composition of about 0.01% to about 0.08% based on total weight of the composition.
In embodiments of the invention, the present invention relates to a fast dissolving film composition comprising of
a) about 45.0% w/w to about 50.0% w/w paracetamol based on total weight of film composition;
b) about 15.0% w/w to about 25.0% w/w hydroxypropyl methylcellulose based on total weight of film composition;
c) about 1.0% w/w to about 5.0% w/w hydroxypropyl b-cyclodextrin based on total weight of film composition;
d) about 5.0% w/w to about 10.0% w/w silicified microcrystalline cellulose based on total weight of film composition;
e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
f) sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
g) about 1.0% w/w to about 5.0% w/w of glycerol based on the total weight of film composition; and
h) at least one excipient selected from coloring agents and flavoring agents.
In further embodiments of the invention, the present invention relates to a fast dissolving film composition consisting essentially of
a) about 45.0% w/w to about 50.0% w/w paracetamol based on total weight of film composition;
b) about 15.0% w/w to about 25.0% w/w hydroxypropyl methylcellulose based on total weight of film composition;
c) about 1.0% w/w to about 5.0% w/w hydroxypropyl b-cyclodextrin based on total weight of film composition;
d) about 5.0% w/w to about 10.0% w/w silicified microcrystalline cellulose based on total weight of film composition;
e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
f) sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
g) about 1.0% w/w to about 5.0% w/w of glycerol based on the total weight of film composition; and
h) at least one excipient selected from coloring agents and flavoring agents.
In another embodiment of the invention, the present invention relates to a fast dissolving film composition consisting of
a) about 45.0% w/w to about 50.0% w/w paracetamol based on total weight of film composition;
b) about 15.0% w/w to about 25.0% w/w hydroxypropyl methylcellulose based on total weight of film composition;
c) about 1.0% w/w to about 5.0% w/w hydroxypropyl b-cyclodextrin based on total weight of film composition;
d) about 5.0% w/w to about 10.0% w/w silicified microcrystalline cellulose based on total weight of film composition;
e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
f) sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
g) about 1.0% w/w to about 5.0% w/w of glycerol based on the total weight of film composition; and
h) at least one excipient selected from coloring agents and flavoring agents.
It is desirable that the oral film formulation of the present invention is formed into a thin film while maintaining tensile strength and toughness at desired levels.
In one embodiment, the oral film formulation of the present invention has a thickness of about 50 pm to about 1500 pm. The oral film formulation of the present invention has a size of about 1 cm2 to about 12 cm2, preferably 2 cm2 to about 10 cm2.
The following examples are provided to illustrate the present invention. It is understood, however, that the invention is not limited to the specific conditions or details described in the examples below. The examples should not be construed as limiting the invention as the examples merely provide specific methodology useful in the understanding and practice of the invention and its various aspects. While certain preferred and alternative embodiments of the invention have been set forth for
purposes of disclosing the invention, modification to the disclosed embodiments can occur to those who are skilled in the art.
Example 1:
Oral disintegrating film with following solvent system composition
1. Manufacturing process of oral disintegrating film
1.1 Preparation of HPMC Base:
Weighed quantity of hot purified water was taken in a beaker and slowly HPMC powder was added to it under continuous stirring, then purified water was to it and stir it for 7-10 minutes and kept aside for overnight for removing air bubbles.
1.2 Formulation:
1.2.1 Weighed quantity of purified water was taken in a beaker and paracetamol was added to it and stir it for 4-5 minutes, then sucralose was added to it and stir it for 4-5 minutes.
1.2.2 Weighed quantity of prosolv ODT G2 was added to step No. 1.2.1 and stir it for 4-5 minutes, then Hydroxypropyl - Betacyclodextrin was added to it and stir it for 2 - 3 minutes.
1.2.3 Weighed quantity of ammonium glycyrrhizinate was added to step No. 1.2.2 and stir it for 4-5 minutes, then xylitol was added to it and stir it for 7-10 minutes.
1.2.4 Weighed quantity of HPMC base was added to step No. 1.2.3 and sonicate it for 12-15 minutes, glycerol then was added to it and stir it for 7-10 minutes.
1.2.5 Weighed quantity of chocolate flavor was added to step No. 1.2.4 and stir it for 12-15 minutes, then cooling agent flavor was added to it and stir it for 12- 15 minutes
1.2.6 Weighed quantity of sodium carbonate was added to step No. 1.2.5 and stir it for 12-15 minutes, then citric acid was added to it and stir it for 12-15 minutes, then solid choco color was added to it and stir it for 12-15 minutes and then kept aside for overnight for removing air bubbles.
Comparative Examples 1-5:
Pharmaceutical compositions for oral film preparations were shown in Table- 1. The pH values, bitter taste scores, were evaluated based on the following criteria.
• Bitter taste score: 10 men and women aged 25 to 40 years were allowed to feel the taste of the compositions, the taste was scored based on the following criteria and those scores were averaged (the values were rounded off to two decimals).
0: No bitter taste
1 : Tasteless
2: Bitter taste was perceptible
3: Slightly bitter taste was felt
4: Bitter taste was felt
5: Strong bitter taste was felt
The compositions of Table 1 are not in scope of the claims
Table-1
Examples 2- 7:
Table-2
As can be seen from table 2, when the mixture of sodium carbonate, citric acid and Magnesium aluminometasilicate are used in ratio of 1 : 4.5: 7.5 (Example-5), the
bitter taste of paracetamol was effectively masked. The composition of Example-5 comprises of 0.15% w/w of sodium carbonate, 0.7% w/w of citric acid and 1.2% of magnesium aluminometasilicate for which the taste of paracetamol was masked.
Example - 8: Dissolution
Dissolution profile of Example - 5 was done in pH 1.2 Media (HC1 Buffer), pH 4.5 Media (acetate buffer) and pH 6.8 Media (Phosphate buffer) in paddle apparatus at 50 RPM with volume of 900 mL and release profile is as depicted in Table -3.
Table - 3
Claims
1. A fast dissolving film composition comprising
a) paracetamol or pharmaceutically acceptable salt thereof;
b) solubilizer selected from the group consisting of benzyl alcohol,
hydroxypropyl- P-cyclodextrin, polyvinylpyrrolidone, and sulfobutylether-P-cyclodextrin;
c) disintegrant selected from the group consisting of sodium starch
glycolate, pregelatinized starch, carboxymethyl cellulose, and silicified microcrystalline cellulose; and
d) taste masking agent; wherein taste masking agent is a mixture of
sodium carbonate, citric acid and magnesium aluminometasilicate.
2. The fast dissolving film according to claim 1, wherein the ratio of solubilizer and disintegrant is of about 1 : 3 to about 3: 1.
3. The fast dissolving film according to claim 1, wherein the ratio of sodium carbonate, citric acid and magnesium aluminometasilicate is of about 1 : 4.5: 7.5.
4. The fast dissolving film according to claim 1, further comprising a polymer; wherein the paracetamol or pharmaceutically acceptable salt thereof is present in an amount of at least 1 OOmg or at least 40% w/w by weight based on the total weight of the composition and wherein polymer is selected from group consisting of hydroxypropyl methylcellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol and cellulose acetate phthalate.
5. The fast dissolving film according to claim 1, further comprises a plasticizer selected from group consisting of polyethylene glycol, diethyl phthalate, propylene glycol and glycerol.
6. The fast dissolving film according to claim 1, further comprises a sweetening agent selected from the group consisting of aspartame, sucralose, dextrose, fructose, ammonium glycyrrhizinate, maltose, mannitol, sorbitol and xylitol.
7. The fast dissolving film according to claim 6, wherein the sweetening agent is a mixture of xylitol and sucralose in a ratio of about 3: 1 to about 1 :3.
8. A fast dissolving film composition comprising of
a) at least 40% w/w of paracetamol; and
b) taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
9. The fast dissolving composition according to claim 8, wherein the composition comprises of about 45.0% w/w to about 50.0% w/w paracetamol based on total weight of film composition and tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition.
10. A fast dissolving film composition comprising of
a) about 45.0% w/w to about 50.0% w/w paracetamol based on total weight of film composition;
b) about 15.0% w/w to about 25.0% w/w hydroxypropyl methylcellulose based on total weight of film composition;
c) about 1.0% w/w to about 5.0% w/w hydroxypropyl b-cyclodextrin based on total weight of film composition;
d) about 5.0% w/w to about 10.0% w/w silicified microcrystalline cellulose based on total weight of film composition;
e) tasting masking agent mixture consisting about 0.1% w/w to about 0.5% w/w sodium carbonate, about 0.5% w/w to about 1.0 w/w citric acid and about 0.5% w/w to about 2.0% w/w magnesium aluminometasilicate based on total weight of film composition;
f) sweetening agent mixture consisting about 3% w/w to about 5% w/w sucralose and about 1.0% w/w to about 3% w/w of xylitol based on the total weight of film composition;
g) about 1.0% w/w to about 5.0% w/w of glycerol based on the total weight of film composition; and
h) at least one excipient selected from coloring agents and flavoring agents.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19788038.8A EP3781145A4 (en) | 2018-04-18 | 2019-04-17 | Oral disintegrating film compositions of paracetamol |
CN201980004250.3A CN111065384A (en) | 2018-04-18 | 2019-04-17 | Composition of orally disintegrating film of paracetamol |
RU2020137701A RU2755087C1 (en) | 2018-04-18 | 2019-04-17 | Composite compound of paracetamol for oral use |
US16/618,159 US11202756B2 (en) | 2018-04-18 | 2019-04-17 | Oral disintegrating film compositions of paracetamol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841014660 | 2018-04-18 | ||
IN201841014660 | 2018-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019202521A1 true WO2019202521A1 (en) | 2019-10-24 |
Family
ID=68239394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/053158 WO2019202521A1 (en) | 2018-04-18 | 2019-04-17 | Oral disintegrating film compositions of paracetamol |
Country Status (5)
Country | Link |
---|---|
US (1) | US11202756B2 (en) |
EP (1) | EP3781145A4 (en) |
CN (1) | CN111065384A (en) |
RU (1) | RU2755087C1 (en) |
WO (1) | WO2019202521A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110840863A (en) * | 2019-12-06 | 2020-02-28 | 北京斯利安药业有限公司 | Oral instant film agent of alexanide and preparation method thereof |
EP4081218A4 (en) * | 2019-12-23 | 2023-12-06 | Shilpa Medicare Limited | Orally dissolving formulations of prucalopride |
EP4125942A4 (en) * | 2020-03-23 | 2024-04-10 | Aavishkar Oral Strips Private Ltd | Taste masked and rapidly disintegrating ultra thin iron orodispersible film and a process thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0203768A2 (en) * | 1985-05-31 | 1986-12-03 | Warner-Lambert Company | A therapeutic effervescent composition and a method of preparing the same |
WO2013175511A1 (en) * | 2012-05-24 | 2013-11-28 | V.B. Medicare Pvt. Ltd. | Taste masked pharmaceutical compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0421825A1 (en) | 1989-08-11 | 1991-04-10 | Kadem Farmaseutiese Produktie B.K. | Paracetamol solutions |
US7067116B1 (en) * | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
KR20030054221A (en) * | 2001-12-24 | 2003-07-02 | 애경산업(주) | Composite film composition for oral cavity and preparing method thereof |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
CN1679525A (en) | 2005-01-12 | 2005-10-12 | 复旦大学 | Oral disintegrant of compound paracetamol |
WO2008149440A1 (en) * | 2007-06-07 | 2008-12-11 | Sato Pharmaceutical Co., Ltd. | Medicinal film preparation with rapidly dissolving property and flexibility |
CN102349883A (en) * | 2011-10-13 | 2012-02-15 | 嘉兴富特吉生物科技有限公司 | Acetaminophen oral instant membrane and preparation method thereof |
WO2015023889A1 (en) * | 2013-08-16 | 2015-02-19 | Luminus Biosciences Inc. | Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
KR101516875B1 (en) * | 2013-08-21 | 2015-04-30 | (주)우신메딕스 | The oral disintegration film formulation of sildenafil citrate having improved dispersion, and manufacturing thereof |
TR201618030T2 (en) | 2014-08-14 | 2018-09-21 | Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi | Tastedly corrected paracetamol formulations. |
-
2019
- 2019-04-17 RU RU2020137701A patent/RU2755087C1/en active
- 2019-04-17 WO PCT/IB2019/053158 patent/WO2019202521A1/en unknown
- 2019-04-17 EP EP19788038.8A patent/EP3781145A4/en not_active Withdrawn
- 2019-04-17 US US16/618,159 patent/US11202756B2/en active Active
- 2019-04-17 CN CN201980004250.3A patent/CN111065384A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0203768A2 (en) * | 1985-05-31 | 1986-12-03 | Warner-Lambert Company | A therapeutic effervescent composition and a method of preparing the same |
WO2013175511A1 (en) * | 2012-05-24 | 2013-11-28 | V.B. Medicare Pvt. Ltd. | Taste masked pharmaceutical compositions |
Non-Patent Citations (1)
Title |
---|
See also references of EP3781145A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110840863A (en) * | 2019-12-06 | 2020-02-28 | 北京斯利安药业有限公司 | Oral instant film agent of alexanide and preparation method thereof |
CN110840863B (en) * | 2019-12-06 | 2022-05-17 | 北京斯利安药业有限公司 | Oral quick-dissolving film agent of alexanide and preparation method thereof |
EP4081218A4 (en) * | 2019-12-23 | 2023-12-06 | Shilpa Medicare Limited | Orally dissolving formulations of prucalopride |
EP4125942A4 (en) * | 2020-03-23 | 2024-04-10 | Aavishkar Oral Strips Private Ltd | Taste masked and rapidly disintegrating ultra thin iron orodispersible film and a process thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3781145A1 (en) | 2021-02-24 |
US20210137831A1 (en) | 2021-05-13 |
CN111065384A (en) | 2020-04-24 |
RU2755087C1 (en) | 2021-09-13 |
EP3781145A4 (en) | 2021-12-29 |
US11202756B2 (en) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10744176B2 (en) | Edible oral strip or wafer dosage form containing ion exchange resin for taste masking | |
JP5242543B2 (en) | Solid dosage form containing a taste masked active agent | |
ES2908977T3 (en) | Solid pharmaceutical dosage form for delivering at least two active pharmaceutical ingredients into the oral cavity | |
JP2008517935A (en) | Pharmaceutical composition comprising diclofenac | |
US11202756B2 (en) | Oral disintegrating film compositions of paracetamol | |
US10335443B2 (en) | Orodispersible film | |
WO2013024373A1 (en) | Pharmaceutical composition comprising cefuroxime | |
JP2019523212A (en) | Fast-acting orally disintegrating film for local anesthetic administration | |
Jaiswal | Oral strip technology: A review | |
KR101462018B1 (en) | Orally Disintegrating Film Formulation Containing Entecavir | |
AU2018216886B2 (en) | A lozenge | |
JP2004269513A (en) | Solid preparation | |
RU2729659C1 (en) | Dosage form for releasing drotaverine in oral cavity | |
Gupta et al. | An overview of mouth dissolving films: Formulation aspects | |
US20240180821A1 (en) | Orally disintegrating film composition of ketorolac and a method of preparation thereof | |
WO2022201090A1 (en) | Orally disintegrating film composition of ketorolac and a method of preparation thereof | |
BR112020017468A2 (en) | ORAL DOSAGE FORM WITH THEOBROMINE FREE COCOA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19788038 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019788038 Country of ref document: EP Effective date: 20201118 |